Tempus AI announced the launch of Tempus Loop, a new oncology-focused platform designed for target discovery and validation. Loop represents Tempus’ proprietary approach to novel target identification, integrating real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI.
The platform aims to rapidly uncover insights for pre-clinical therapeutic development, addressing the industry challenge of translating promising preclinical experiments into effective treatments. Loop's approach is powerful because it uses Tempus’ rich RWD to identify patient subpopulations with similar clinical, pathologic, and molecular patterns.
Tempus has already deployed its Loop platform to prioritize drug targets for a large pharmaceutical company, confirming and validating these targets within a year, which is a significant acceleration of the standard discovery timeline. This seamless integration of RWD to patient-derived organoids and back enables rapid hypothesis generation and testing in relevant disease models.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.